Literature DB >> 25001265

Radiation therapy for liver tumors: ready for inclusion in guidelines?

Shyam K Tanguturi1, Jennifer Y Wo1, Andrew X Zhu1, Laura A Dawson1, Theodore S Hong2.   

Abstract

Despite the historically limited role of radiotherapy in the management of primary hepatic malignancies, modern advances in treatment design and delivery have renewed enthusiasm for radiation as a potentially curative treatment modality. Surgical resection and/or liver transplantation are traditionally regarded as the most effective forms of therapy, although the majority of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma present with locally advanced or unresectable disease on the basis of local vascular invasion or inadequate baseline hepatobiliary function. In this context, many efforts have focused on nonoperative treatment approaches including novel systemic therapies, transarterial chemoembolization, ethanol ablation, radiofrequency ablation, and stereotactic body radiation therapy (SBRT). This review aims to summarize modern advances in radiotherapy, particularly SBRT, in the treatment of primary hepatic malignancies. ©AlphaMed Press.

Entities:  

Keywords:  Cholangiocarcinoma; Hepatobiliary cancer; Hepatocellular carcinoma; Radiation therapy; Stereotactic body radiation therapy

Mesh:

Year:  2014        PMID: 25001265      PMCID: PMC4122485          DOI: 10.1634/theoncologist.2014-0097

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  108 in total

1.  The use of active breathing control (ABC) to reduce margin for breathing motion.

Authors:  J W Wong; M B Sharpe; D A Jaffray; V R Kini; J M Robertson; J S Stromberg; A A Martinez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-01       Impact factor: 7.038

2.  Inter- and intrafraction variability in liver position in non-breath-hold stereotactic body radiotherapy.

Authors:  Robert B Case; Jan-Jakob Sonke; Douglas J Moseley; John Kim; Kristy K Brock; Laura A Dawson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-07-21       Impact factor: 7.038

3.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

4.  Changes in functional vascularity and cell number following x-irradiation of a murine carcinoma.

Authors:  J J Clement; C W Song; S H Levitt
Journal:  Int J Radiat Oncol Biol Phys       Date:  1976 Jul-Aug       Impact factor: 7.038

5.  Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.

Authors:  Wen-Yen Huang; Yee-Min Jen; Meei-Shyuan Lee; Li-Ping Chang; Chang-Ming Chen; Kai-Hsiung Ko; Kuen-Tze Lin; Jang-Chun Lin; Hsing-Lung Chao; Chun-Shu Lin; Yu-Fu Su; Chao-Yueh Fan; Yao-Wen Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-17       Impact factor: 7.038

6.  An application of dose volume histograms to the treatment of intrahepatic malignancies with radiation therapy.

Authors:  T S Lawrence; R J Tesser; R K ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-10       Impact factor: 7.038

7.  Computer simulation of cytotoxic and vascular effects of radiosurgery in solid and necrotic brain metastases.

Authors:  M Kocher; H Treuer; J Voges; M Hoevels; V Sturm; R P Müller
Journal:  Radiother Oncol       Date:  2000-02       Impact factor: 6.280

8.  Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy.

Authors:  J M Robertson; T S Lawrence; L M Dworzanin; J C Andrews; S Walker; M L Kessler; D J DuRoss; W D Ensminger
Journal:  J Clin Oncol       Date:  1993-07       Impact factor: 44.544

9.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients.

Authors:  H Blomgren; I Lax; I Näslund; R Svanström
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

10.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

Authors:  Alejandro Forner; Carmen Ayuso; María Varela; Jordi Rimola; Amelia J Hessheimer; Carlos Rodriguez de Lope; María Reig; Luís Bianchi; Josep M Llovet; Jordi Bruix
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

View more
  19 in total

1.  SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center.

Authors:  Haoming Qiu; Michael J Moravan; Michael T Milano; Kenneth Y Usuki; Alan W Katz
Journal:  J Gastrointest Cancer       Date:  2018-12

Review 2.  Radiotherapy for liver tumors.

Authors:  Florence K Keane; Shyam K Tanguturi; Andrew X Zhu; Laura A Dawson; Theodore S Hong
Journal:  Hepat Oncol       Date:  2015-04-20

Review 3.  The emerging role of stereotactic radiotherapy in gastrointestinal malignancies: a review of the literature and analysis from the Irish perspective.

Authors:  Siobhra O'Sullivan; Daniel N Cagney
Journal:  Ir J Med Sci       Date:  2018-02-08       Impact factor: 1.568

4.  NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.

Authors:  Al B Benson; Michael I D'Angelica; Daniel E Abbott; Thomas A Abrams; Steven R Alberts; Daniel Anaya Saenz; Chandrakanth Are; Daniel B Brown; Daniel T Chang; Anne M Covey; William Hawkins; Renuka Iyer; Rojymon Jacob; Andrea Karachristos; R Kate Kelley; Robin Kim; Manisha Palta; James O Park; Vaibhav Sahai; Tracey Schefter; Carl Schmidt; Jason K Sicklick; Gagandeep Singh; Davendra Sohal; Stacey Stein; G Gary Tian; Jean-Nicolas Vauthey; Alan P Venook; Andrew X Zhu; Karin G Hoffmann; Susan Darlow
Journal:  J Natl Compr Canc Netw       Date:  2017-05       Impact factor: 11.908

5.  The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy.

Authors:  Ying Xu; Yi Yang; Lu Li; Feng Ye; Xinming Zhao
Journal:  Front Oncol       Date:  2022-05-24       Impact factor: 5.738

Review 6.  Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: imaging evaluation post treatment.

Authors:  Trenton Kellock; Teresa Liang; Alison Harris; Devin Schellenberg; Roy Ma; Stephen Ho; Wan Wan Yap
Journal:  Br J Radiol       Date:  2018-02-01       Impact factor: 3.039

7.  Assessing the uncertainty in a normal tissue complication probability difference (∆NTCP): radiation-induced liver disease (RILD) in liver tumour patients treated with proton vs X-ray therapy.

Authors:  Keiji Kobashi; Anussara Prayongrat; Takuya Kimoto; Chie Toramatsu; Yasuhiro Dekura; Norio Katoh; Shinichi Shimizu; Yoichi M Ito; Hiroki Shirato
Journal:  J Radiat Res       Date:  2018-03-01       Impact factor: 2.724

8.  SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy.

Authors:  Michael I Koukourakis; Alexandra Giatromanolaki; Konstantina Fylaktakidou; Efthimios Sivridis; Christos E Zois; Dimitra Kalamida; Achilleas Mitrakas; Stamatia Pouliliou; Ilias V Karagounis; Konstantinos Simopoulos; David J P Ferguson; Adrian L Harris
Journal:  Invest New Drugs       Date:  2018-01-31       Impact factor: 3.850

9.  CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors.

Authors:  Olga R Brook; Eavan Thornton; Mishal Mendiratta-Lala; Anand Mahadevan; Vassilious Raptopoulos; Alexander Brook; Robert Najarian; Robert Sheiman; Bettina Siewert
Journal:  Gastroenterol Res Pract       Date:  2015-06-29       Impact factor: 2.260

10.  Normal tissue radioprotection by amifostine via Warburg-type effects.

Authors:  Michael I Koukourakis; Alexandra Giatromanolaki; Christos E Zois; Dimitra Kalamida; Stamatia Pouliliou; Ilias V Karagounis; Tzu-Lan Yeh; Martine I Abboud; Timothy D W Claridge; Christopher J Schofield; Efthimios Sivridis; Costantinos Simopoulos; Savvas P Tokmakidis; Adrian L Harris
Journal:  Sci Rep       Date:  2016-08-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.